The Role of Peptides in Retroviral Research: From Molecular Tools to Therapeutic Breakthroughs by Dr. Oliver Reimann

1. The Ongoing Challenge of Retroviral Diseases

Despite decades of progress, retroviral infections such as HIV remain a major global health burden.
Today, more than 40 million people live with HIV, and approximately 1 million new infections occur every year.
Understanding viral diversity, latent reservoirs, and the rapid mutation rates that lead to drug resistance demands precise molecular tools and novel therapeutic approaches, a need that peptides are uniquely positioned to meet.

2. Peptides: The Versatile Molecular Workhorses

Peptides, short chains of amino acids typically up to 50 residues, have become indispensable tools in virology and immunology.
Produced mainly via solid-phase peptide synthesis (SPPS), they can mimic viral or host protein domains, inhibit viral entry or replication, and serve as vaccine antigens to trigger targeted immune responses.

A historical milestone in peptide therapeutics was Enfuvirtide (Fuzeon), the first peptide drug to block HIV-1 entry into host cells.
When approved by the FDA in 2003 and marketed by Roche, it demonstrated the immense potential of peptides as medicines.
With over 100 synthetic steps, Fuzeon was once considered too complex to be commercially viable, yet it went on to generate more than 250 million USD in annual revenue, reshaping the perception of peptides in pharma forever.

3. Technological Acceleration: From HTS to AI-Driven Design

The peptide field has evolved rapidly with the advent of high-throughput screening (HTS) methods, such as phage or RNA display, enabling the identification of binding sequences or vaccine candidates at unprecedented speed.
Modern chemistry has further expanded possibilities through the use of unnatural amino acids, peptide–protein conjugations, and macrocyclic designs.

Meanwhile, AI and machine learning are revolutionizing both peptide discovery and manufacturing.

Automation now supports efficient synthesis and purification, while novel commercial building blocks enable rapid, scalable, and cost-effective peptide production, paving the way for entirely new molecular classes, such as Merck’s oral PCSK9 inhibitor, MK-0616.

4. From Prediction to Peptide Vaccines: A Case Study Approach

Dr. Reimann emphasized the role of peptide libraries in vaccine development.
Using bioinformatic tools like IEDB, NetMHCpan, MHCflurry, or BepiPred, researchers can predict T- and B-cell epitopes, the immunogenic “hotspots” of viral proteins.

These predicted peptides are synthesized and tested via in vitro and in vivo assays, including ELISPOT, ELISA, cytotoxicity tests, and neutralization assays, forming the foundation for next-generation peptide-based vaccines.

5. Intavis Peptide Services: Empowering Discovery and Development

With nearly 30 years of experience, Intavis Peptide Services (IPS) in Tübingen provides a one-stop solution for peptide-based R&D and early-stage drug development.
Founded by Dr. Steffen Hüttner, Dr. Dr. Saskia Biskup, Dr. Dirk Biskup, and Dr. Klaus Maleck, the company employs a multidisciplinary team of around more than 60 experts, chemists, biologists, and engineers, united by a mission to deliver precision-engineered peptides that advance science and therapy.
IPS offers:

• Peptide arrays (SPOT and CelluSPOT®) with up to 100,000 peptides
• Custom peptide synthesis from mg to g scale
• Peptide libraries in 96-well and reactor formats
• Advanced-grade and GMP manufacturing for vaccine and clinical applications

The company’s expertise extends to therapeutic cancer vaccine projects, including the manufacturing of neoantigen peptides for glioblastoma studies, where improved overall survival times have been observed.

As peptide science continues to intersect with AI, immunotherapy, and personalized medicine, Intavis Peptide Services remains committed to supporting researchers and pharmaceutical partners worldwide.
Through fast turnaround times, high-quality synthesis, and collaborative partnerships, IPS stands as a trusted ally in the race to translate molecular innovation into real-world therapies.

Bibliography

Author: Dr. Oliver Reimann